Long-term prescribed drug use in stage I–III rectal cancer patients in Sweden, with a focus on bowel-regulating drugs after surgical and oncological treatment
Journal of Cancer Survivorship · 2025
DOI: 10.1007/s11764-024-01548-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Survivorship, 2025. Verfasst von Sol Erika Boman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, 17176, Stockholm, Sweden. Hauptthemen laut MEDLINE: Rectal Neoplasms, Drug Prescriptions. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Strategic Research Program in Epidemiology at Karolinska Institutet, The Swedish Cancer and Allergy foundation, Stockholm Cancer Society and supported by grants provided by the Regional Agreement on Medical Training and Clinical Research (ALF) between the Stockholm Count….
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
To describe long-term prescribed drug use after rectal cancer treatment.
Methods
We identified 12,871 rectal cancer patients without distant metastasis between 2005 and 2016 and 64,341 matched population comparators using CRCBaSe (a Swedish nationwide register linkage of colorectal cancer patients). Mean defined daily doses (DDDs) of drug dispensing during relapse-free follow-up were calculated by Anatomical Therapeutic Chemical drug categories. Incidence rate ratios (IRRs) and 95% confidence intervals (CIs) from negative binomial regression were used to compare drug dispensing between patients and comparators.
Results
The overall pattern of drug dispensing was similar among cancer survivors and comparators, although patients had higher mean DDDs of drugs regulating the digestive system. Excess dispensing of drugs for constipation (IRR, 3.35; 95% CI, 3.12–3.61), diarrhea (IRR, 6.43; 95% CI, 5.72–7.22), functional gastrointestinal disorders (IRR, 3.78; 95% CI, 3.15–4.54), and vitamin and mineral supplements (IRR, 1.37; 95% CI, 1.24–1.50) was observed up to 10 years after surgery. Treatment with Hartmann’s procedure was associated with higher dispensing rates of digestive drugs compared to surgery with anterior resection and abdominoperineal resection but the association was attributed to higher use of diabetic drugs. Additionally, excess digestive drug dispensing was associated with more advanced cancer stage but not with (chemo)radiotherapy treatment.
Conclusions
Excess drug use after rectal cancer is primarily driven by bowel-regulating drugs and is not modified by surgical or oncological treatment. Implications for Cancer Survivors The excess use of bowel-regulating drugs after rectal cancer indicated long-standing postsurgical gastrointestinal morbidity and need of prophylaxis. Reassuringly, no excess use of other drug classes was noted long term.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, 17176, Stockholm, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, 17176, Stockholm, Sweden.
- Division of Gastroenterology, Medical Unit Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, 75185, Uppsala, Sweden.
- Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, 17176, Stockholm, Sweden. sandra.eloranta@ki.se.
Förderung
- Strategic Research Program in Epidemiology at Karolinska Institutet
- The Swedish Cancer and Allergy foundation
- Stockholm Cancer Society and supported by grants provided by the Regional Agreement on Medical Training and Clinical Research (ALF) between the Stockholm Count…
- Radiumhemmets Forskningsfonder
- The Swedish Cancer Society
- Karolinska Institute
Zitieren
APA
Boman, S. E., Fuentes, S., Nordenvall, C., Martling, A., Chen, L., Glimelius, I., Neovius, M., Smedby, K. E., & Eloranta, S. (2025). Long-term prescribed drug use in stage I–III rectal cancer patients in Sweden, with a focus on bowel-regulating drugs after surgical and oncological treatment. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-024-01548-9
Vancouver
Boman SE, Fuentes S, Nordenvall C, Martling A, Chen L, Glimelius I, et al. Long-term prescribed drug use in stage I–III rectal cancer patients in Sweden, with a focus on bowel-regulating drugs after surgical and oncological treatment. Journal of Cancer Survivorship. 2025. doi:10.1007/s11764-024-01548-9
BibTeX
@article{Boman2025,
author = {Boman, Sol Erika and Fuentes, Stina and Nordenvall, Caroline and Martling, Anna and Chen, Lingjing and Glimelius, Ingrid and Neovius, Martin and Smedby, Karin E and Eloranta, Sandra},
title = {Long-term prescribed drug use in stage I–III rectal cancer patients in Sweden, with a focus on bowel-regulating drugs after surgical and oncological treatment},
journal = {Journal of Cancer Survivorship},
year = {2025},
doi = {10.1007/s11764-024-01548-9}
}
EUVIMED